Current and future treatment options in idiopathic pulmonary fibrosis

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 3, 2010, Pages 158-172

  Hauber, Hans Peter ^a   Blaukovitsch, Markus ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Acetylcysteine; Azathioprine; Glucocorticosteroid; Idiopathic pulmonary fibrosis; Treatment

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT; AZATHIOPRINE; BIBF 1120; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENDOTHELIN RECEPTOR ANTAGONIST; FG 3019; GAMMA INTERFERON; GAMMA INTERFERON 1BETA; GLUCOCORTICOID; HEPARIN; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; MS 80; PENICILLAMINE; PHENPROCOUMON; PIRFENIDONE; PLACEBO; PREDNISONE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW SUPPRESSION; CANCER RISK; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION RISK; LIVER TOXICITY; LOW DRUG DOSE; LUNG BIOPSY; LUNG EMBOLISM; LUNG FUNCTION; LUNG INJURY; LUNG TRANSPLANTATION; NAUSEA; NAUSEA AND VOMITING; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; SIDE EFFECT; STOMACH DISCOMFORT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 77958475711     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810792231878     Document Type: Article

References (166)

1. Maple, D. W.; Hunt, W. C.; Utton, R.; Baumgartner, K. B.; Samet, J. M.; Coultas, D. B. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax, 1998, 53(6), 469-476.
2. Hubbard, R.; Venn, A.; Lewis, S.; Britton, J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med., 2000, 161(1), 5-8.
3. Demedts, M.; Well, A. U.; Antó, J. M.; Costabel, U.; Hubbard, R.; Cullinan, P.; Slabbynck, H.; Rizzato, G.; Poletti, V.; Verbeken, E. K.; Thomeer, M. J.; Kokkarinen, J.; Dalphin, J. C.; Taylor, A. N. Interstitial lung diseases: an epidemiological overview. Eur. Respir. J., 2001, 18, 2s-16s.
4. Raghu, G.; Weycker, D.; Edelsberg, J.; Bradford, W. Z.; Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2006, 174(7), 810-6.
5. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med., 2000, 161(2), 646-64.
6. Flaherty, K. R.; Martinez, F. J.; Travis, W.; Lynch, J. P. 3rd. Nonspecific interstitial pneumonia (NSIP). Semin. Respir. Crit. Care Med., 2001, 22(4), 423-34.
7. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med., 2002, 165(2), 277-304.
8. Crystal, R. G.; Fulmer, J. D.; Roberts, W. C.; Moss, M. L.; Line, B. R.; Reynolds, H. Y. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann. Intern. Med., 1976, 85(6), 769-88.
9. Keogh, B. A.; Crystal, R. G. Alveolitis: the key to interstitial lung disorders. Thorax, 1982, 37(1), 1-10.
10. Selman, M.; King, T. E.; Pardo, A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopahtic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med., 2001, 134(2), 136-51.
11. Strieter, R. M.; Mehrad, B. New mechanisms of pulmonary fibrosis. Chest, 2009, 136(5), 1364-70.
12. Clark, R. A. Basis of cutaneous wound repair. J. Dermatol. Surg. Oncol., 1993, 19(8), 693-706.
13. Keane, M. P.; Belperio, J. A.; Henson, P. M. In Textbook of respiratory medicine 4th ed.; Mason, R. J.; Broaddus, V. C.; Murray, J. F., Eds.; Elsevier Saunders: Philadelphia, PA, 2005, pp. 449-90.
14. Wallace, W. A. H.; Fitch, P. M.; Simpson, J. A.; Howie, S. E. M. Inflammation-associated remodelling and fibrosis in the lung - a process and an end point. Int. J. Exp. Pathol., 2007, 88(2), 103-10.
15. Corrin, B.; Dewar, A.; Rodriguez-Roisin, R.; Turner-Warwick, M. Fine structural changes in cryptogenic alveolitis and asbestosis. J. Pathol., 1985, 147(2), 107-19.
16. rd; Boldt, J.; King, T. E. Jr; Crouch, E.; Vartio, T.; McDonald, J. A. An immunohistochemical study of architectural remodelling and connective tissue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis.,1989, 140(6), 1693-703.
17. McDonald, J. A. Idiopathic pulmonary fibrosis. A paradigm for lung injury and repair. Chest, 1991, 99(Suppl 3), 87S-93S.
18. Strieter, R. M.; Gomperts, B. N.; Keane, M. P. The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest., 2007, 117(3), 549-56.
19. Strieter, R. M. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest, 2005, 128(Suppl 5), 526S-532S.
20. Sime, P. J.; Xing, Z.; Graham, F. L.; Csaky, K. G.; Gauldie, J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest., 1997, 100(4), 768-76.
21. Lee, C. G.; Cho, S. J.; Kang, M. J.; Chapoval, S. P.; Lee, P. J.; Noble, P. W.; Yehualaeshet, T.; Lu, B.; Flavell, R. A.; Milbrandt, J.; Homer, R. J.; Elias, J. A. Early growth response gene 1- mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J. Exp. Med., 2004, 200(3), 377-89.
22. Willis, B. C.; Liebler, J. M.; Luby-Phelps, K.; Nicolson, A. G.; Crandall, E. D.; du Bois, R. M.; Borok, Z. Induction of epithelialmesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol., 2005, 166(5), 1321-32.
23. Leask, A.; Abraham, D. J. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell Biol., 2003, 81(6), 355-63.
24. Bonner, J. C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev., 2004, 15(4), 255-73.
25. Kolodsick, J. E.; Toews, G. B.; Jakubzick, C.; Hogaboam, C.; Moore, T. A.; McKenzie, A.; Wilke, C. A.; Chrisman, C. J.; Moore, B. B. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis. J. Immunol., 2004, 172(7), 4068-76.
26. Fichtner-Feigl, S.; Strober, W.; Kawakami, K.; Puri, R. K.; Kitani, A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med., 2006, 12(1), 99-106.
27. Liu, T.; Jin, H.; Ullenbruch, M.; Hu, B.; Hashimoto, N.; Moore, B.; McKenzie, A.; Lukacs, N. W.; Phan, S. H. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J. Immunol., 2004, 173(5), 3425-31.
28. Liu, T.; Dhanasekaran, S. M.; Jin, H.; Hu, B.; Tomlins, S. A.; Chinnaiyan, A. M.; Phan, S. H. FIZZ1 stimulation of myofibroblast differentiation. Am. J. Pathol., 2004, 164(4), 1315-26.
29. Agostini, C.; Gurrieri, C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc., 2006, 3(4), 357-63.
30. Gharaee-Kermani, M.; Denholm, E. M.; Phan, S. H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem., 1996, 271(30), 17779-84.
31. Suga, M.; Iyonaga, K.; Ichiyasu, H.; Saita, N.; Yamasaki, H.; Ando, M. Clinical significance of MCP-1 levels in BALF and serum of patients with interstitial lung diseases. Eur. Respir. J., 1999, 14(2), 376-82.
32. Zuo, F.; Kaminski, N.; Eugui, E.; Allard, J.; Yahkini, Z.; Ben-Dor, A,; Lollini, L.; Morris, D.; Kim, Y.; DeLustro, B.; Sheppard, D.; Pardo, A.; Selman, M.; Heller, R. A. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA, 2002, 99(9), 6292-7.
33. Marchal-Sommé, J.; Uzunhan, Y.; Marchand-Adam, S.; Valeyre, D.; Soumelis, V.; Crestani, B.; Soler, P. Cutting edge: nonproliferating mature immune cells from a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J. Immunol., 2006, 176(10), 5735-9.
34. Attili, A. K.; Kazerooni, E. A.; Gross, B. H.; Flaherty, K. R.; Martinez, F. J. Thoracic lymph node enlargement in usual interstitial pneumonitis and nonspecific-interstitial pneumonitis: prevalence, correlation with disease activity and temporal evolution. J. Thorac. Imaging, 2006, 21(4), 288-92.
35. rd; Hegele, R.; Waldron, J.; Colby, T. V.; Hogg, J. C. Radiologic findings are strongly associated with pathologic diagnosis of usual interstitial pneumonia. Chest, 2003, 124(4), 1215-23.
36. Kasai, H.; Allen, J. T.; Mason, R. M.; Kamimura, T.; Zhang, Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res., 2005, 6, 56.
37. Yao, H. W.; Xie, Q. M.; Chen, J. Q.; Deng, Y. M.; Tang, H. F. TGF-β1 induces alveolar epithelial to mesenchymal transition in vitro. Life Sci., 2004, 76(1), 29-37.
38. Korfei, M.; Ruppert, C.; Mahavadi, P.; Henneke, I.; Markart, P.; Koch, M.; Lang, G.; Fink, L.; Bohle, R. M.; Seeger, W.; Weaver, T. E.; Guenther, A. Epithelial endoplasmatic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2008, 178(8), 838-46.
39. Hyzy, R.; Huang, S.; Myers, J.; Flaherty, K.; Martinez, F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest, 2007, 132(5), 1652-8.
40. Wells, A. U.; Hirani, N.; on behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax, 2008, 63(Suppl 5), v1-v58.
41. Phan, S. H.; Thrall, R. S.; Williams, C. Bleomycin-induced pulmonary fibrosis. Effects of steroid on collagen metabolism. Am. Rev. Respir. Res., 1981, 124(4), 438-4.
42. Richeldi, L.; Davies, H. R. H. R.; Spagnolo, P.; Luppi, F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev., 2003, 3, CD002880.
43. Cegla, U. H. Treatment of idiopathic fibrosing alveolitis. Therapeutic experiences with azathioprine-prednisolone and Dpenicllamine- prednisolone combination therapy Schweiz. Med. Wochenschr., 1977, 107(6), 184-7.
44. Raghu, G.; Depaso, W. J.; Cain, K.; Hammar, S. P.; Wetzel, C. E.; Dreis, D. F.; Hutchinson, J.; Pardee, N. E.; Winterbauer, R. H. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled trial. Am. Rev. Respir. Dis., 1991, 144(2), 29l-6.
45. Cegla, U. H.; Kroidl, R. F.; Meier-Sydow, J.; Thiel, C.; Czarnecki, G. V. Therapy of idiopathic fibrosis of the lung. Pneumonologie, 1975, 152(1-3), 75-92.
46. Winterbauer, R. H.; Hammar, S. P.; Hallman, K. O.; Hays, J. E.; Pardee, N. E.; Morgan, E. H.; Allen, J. D.; Moores, K. D.; Bush, W.; Walker, J. H. Diffuse interstitial pneumonitis. Clincopathologic correlations in 20 patients treated with prednisone/azathioprine. Am. J. Med., 1978, 65(4), 661-72.
47. Hoyles, R. K.; Ellis, R. W.; Wellsbury, J.; Lees, B.; Newlands, P.; Goh, N. S.; Roberts, C.; Desai, S.; Herrick, A. L.; McHugh, N. J.; Foley, N. M.; Pearson, S. B.; Emery, P.; Veale, D. J.; Denton, C. P.; Wells, A. U.; Black, C. M.; du Bois, R. M. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum., 2006, 54(12), 3962-70.
48. Johnson, M. A.; Kwan, S.; Snell, N. J. C.; Nunn, A. I.; Darbyshire, J. H.; Turner-Warwick, M. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax, 1989, 44(4), 280-8.
49. rd; Toews, G.; Kazerooni, E.; Flint, A.; Martinze, F. J. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest, 2000, 117(6), 1619-26.
50. Baughman, R. P.; Lower, E. E. Use of intermittent, intravenous cyclophosphamide for idiopathic fibrosis. Chest, 1992, 102(4), 1090-4.
51. Gay, S. E.; Kazerooni, E. A.; Toews, G. B.; Lynch, J. P. 3rd; Gross, B. H.; Cascade, P. N.; Spizarny, D. L.; Flint, A.; Schork, M. A.; Whyte, R. I.; Popovich, J.; Hyzy, R.; Martinez, F. J. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med., 1998, 157(4), 1063-72.
52. Eliasson, O.; Cole, S. R.; Degraff, A. C. Jr. Adverse effects of cyclophosphamide in idiopathic pulmonary fibrosis. Conn. Med., 1985, 49(5), 286-9.
53. Dayton, C. S.; Schwartz, D. A.; Helmers, R. A.; Pueringer, R. J.; Gilbert, S. R.; Merchant, R. K.; Hunninghake, G. W. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest, 1993, 103(1), 69-73.
54. Collard, H. R.; Ryu, J. H.; Douglas, W. W.; Schwarz, M. I.; Curran-Everett, D.; King, T. E. Jr; Brown, K. K. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest, 2004, 125(6), 2169-74.
55. Gochuico, B. R.; Avila, N. A.; Chow, C. K.; Novero, L. J.; Wu, H. P.; Ren, P.; MacDonald, S. D.; Travis, W. D.; Stylianou, M. P.; Rosas, I. O. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch. Intern. Med., 2008, 168(2), 159-66.
56. Kim, D. S. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr. Opin. Pulm. Med., 2006, 12(5), 346-53.
57. Camus, P.; Fanton, A.; Bonniaud, P.; Camus, C.; Foucher, P. Interstitial lung disease induced by drugs and radiation. Respiration, 2004, 71(4), 301-26.
58. Hoyos, N.; Casanova, A.; Sánchez, S.; Valenzuela, C.; García, A.; Girón, R. M. Polymyositis and interstitial lung disease with a favourable response to corticosteroids and methotrexate. Arch. Bronconeumol., 2007, 43(11), 636-9.
59. Bournia, V. K.; Vlachoyiannopoulos, P. G.; Selmi, C.; Moutsopoulos, H. M.; Gershwin, M. E. Recent advances in the treatment of systemic sclerosis. Clin. Rev. Allergy Immunol., 2009, 36(2-3), 176-200.
60. Zhang, L.; Zhu, Y.; Luo, W. The protective effect of colchicine on bleomycin-induced pulmonary fibrosis in rats. Chin. Med. Sci. J., 1992, 7(1), 58-60.
61. Rennard, S. I.; Bitterman, P. B.; Ozaki, T.; Rom, W. N.; Crystal, R. G. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of possible therapeutic approach to the fibrotic disorders. Am. Rev. Respir. Dis., 1988, 137(1), 181-5.
62. Douglas, W. W.; Ryu, J. H.; Swensen, S. J.; Offord, K. P.; Schroeder, D. R.; Caron, G. M.; DeRemee, R. A. Cochicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am. J. Respir. Crit. Care Med., 1998, 158(1), 220-5.
63. Selman, M.; Carrillo, G.; Salas, J.; Padilla, R. P.; Pérez-Chavira, R.; Sansores, R.; Chapela, R. Cochicine, D-penicllamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest, 1998, 114(2), 507-12.
64. Douglas, W. W.; Ryu, J. H.; Schroeder, D. R. Idiopathic pulmonary fibrosis: Impact of oxygen and cochicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med., 2000, 161(4), 1172-8.
65. Peters, S. G.; McDougall, J. C.; Douglas, W. W.; Coles, D. T.; DeRemee, R. A. Colchicine in the treatment of pulmonary fibrosis. Chest, 1993, 103(1), 101-4.
66. Douglas, W. W.; Ryu, H. J.; Bjoraker, J. A.; Schroeder, D. R.; Myers, J. L.; Tazelaar, H. D.; Swensen, S. J.; Scanlon, P. D.; Peters, S. G.; DeRemee, R. A. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin. Proc., 1997, 72(3), 201-9.
67. Cantin, A. M.; North, S. L.; Fells, G. A.; Hubbard, R. C.; Crystal, R. G. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest., 1987, 79(6), 1665-73.
68. Rahman, I.; MacNee, W. Role of transcription factors in inflammatory lung diseases. Thorax, 1998, 53(7), 601-12.
69. Cantin, A. M.; Hubbard, R. C.; Crystal, R. G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis., 1989, 139(2), 370-2.
70. Meyer, A.; Buhl, R.; Magnussen, H. The effect of oral Nacetlycysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J., 1994, 7(3), 431-6.
71. Meyer, A.; Buhl, R.; Kampf, S.; Magnussen, H. Intravenous Nacetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am. J. Respir. Crit. Care Med., 1995, 152(3), 1055-60.
72. Behr, J.; Maier, K.; Degenkolb, B.; Krombach, F.; Vogelmeier, C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintance immunosuppression. Am. J. Respir. Crit. Care Med., 1997, 156(6), 1897-901.
73. Behr, J.; Degenkolb, B.; Krombach, F.; Vogelmeier, C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur. Respir. J., 2002, 19(5), 906-11.
74. Liu, R. M.; Liu, Y.; Forman, H. J.; Olman, M.; Tarpey, M. M. Glutathione regulates transforming growth factor-beta-stimulated collagen production in fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol., 2004, 286(1), L121-L128.
75. Shahzeidi, S.; Sarnstrand, B.; Jeffery, P. K.; McAnulty, R. J.; Laurent, G. Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. J. Eur. Respir. J., 1991, 4(7), 845-52.
76. Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, R.; Jansen, H. M.; MacNee, W.; Thomeer, M.; Wallaert, B.; Laurent, F.; Nicholson, A. G.; Verbeken, E. K.; Verschakelen, J.; Flower, C. D.; Capron, F.; Petruzzelli, S.; De Vuyst, P.; van den Bosch, J. M.; Rodriguez-Becerra, E.; Corvasce, G.; Lankhorst, I.; Sardina, M.; Montanari, M.; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med., 2005, 353(21), 2229-42.
77. Behr, J.; Demedts, M.; Buhl, R.; Costabel, U.; Dekhuijzen, R.; Jansen, H. M.; MacNee, W.; Thomeer, M.; Wallaert, B.; Laurent, F.; Nicholson, A. G.; Verbeken, E. K.; Verschakelen, J.; Flower, C. D.; Capron, F.; Petruzzelli, S.; De Vuyst, P.; van den Bosch, J. M.; Rodriguez-Becerra, E.; Corvasce, G.; Lankhorst, I.; Sardina, M.; Montanari, M.; IFIGENIA Study Group. Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Resp. Res., 2009, 10, 101.
78. Wells, A. U.; Desai, S. R.; Rubens, M. B.; Goh, N.; Cramer, D.; Nicholson, A.; Colby, T.; du Bois, R.; Hansell, D. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med., 2003, 167(7), 962-9.
79. Kim, D. S.; Park, J. H.; Park, B. K.; Lee, J. S.; Nicholson, A. G.; Colby, T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J., 2006, 27(1), 143-50.
80. Kondoh, Y.; Taniguchi, H.; Kawabata, Y.; Yokoi, T.; Suzuki, K.; Takag, K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest, 1993, 103(6), 1808-12.
81. Parambil, J. G.; Myers, J. L.; Ryu, J. H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest, 2005, 128(5), 3310-5.
82. Akira, M.; Hamada, H.; Sakatani, M.; Kobayashi, C.; Nishioka, M.; Yamamoto, S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am. J. Roentgenol., 1997, 168(1), 79-83.
83. Inase, N.; Sawada, M.; Ohtani, Y.; Isogai, S.; Sakashita, H.; Miyazaki, Y.; Yoshizawa, Y. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern. Med., 2003, 42(7), 565-70.
84. Agarwal, R.; Jindal, S. K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur. J. Intern. Med., 2008, 19(4), 227-35.
85. Nadrous, H. F.; Pellikka, P. A.; Krowka, M. J.; Swanson, K. L.; Chaowalit, N.; Decker, P. A.; Ryu, J. H. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest, 2005, 128(4), 2392-9.
86. Gurujeyalakshmi, G.; Giri, S. N. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp. Lung Res., 1995, 21(5), 791-808.
87. Ziesche, R.; Hofbauer, E.; Wittmann, K.; Petkov, V.; Block, L. H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med., 1999, 314(17), 1264-9.
88. Raghu, G.; Brown, K. K.; Bradford, W. Z.; Starko, K.; Noble, P. W.; Schwartz, D. A.; King, T. E. Jr; Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med., 2004, 350(2), 125-33.
89. King, T. E. Jr; Albera, C.; Bradford, W. C.; Costabel, U.; Homer, P.; Lancster, L.; Noble, P. W.; Sahn, S. A.; Szwarcberg, J.; Thomeer, M.; Valeyre, D.; du Bois, R.; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomized, placebo-controlled trial. Lancet, 2009, 374(9685), 222-8.
90. Antoniou, K. M.; Nicholson, A. G.; Dimadi, M.; Malagari, K.; Latsi, P.; Rapti, A.; Tzanakis, N.; Trigidou, R.; Polychronopoulos, V.; Bouros, D. Long-term clinical effects of interferon gamma-1b and colchicines in idiopathic pulmonary fibrosis. Eur. Respir. J., 2006, 28(3), 496-504.
91. Ward, P. A.; Hunninghake, G. W. Lung inflammation and fibrosis. Am. J. Respir. Crit. Care Med., 1998, 157(4), S123-S129.
92. Kamp, D. W. Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest, 2003, 124(4), 1187-90.
93. Magro, C. M.; Allen, J.; Pope-Harman, A.; Waldman, W. J.; Moh, P.; Rothrauff, S.; Ross, P. Jr. The role of micorvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol., 2003, 119(4), 556-67.
94. Cella, G.; Cipriani, A.; Tommasini, A.; Rampin, E.; Sbarai, A.; Rocconi, R.; Mazzaro, G.; Luzzatto, G. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Semin. Thromb. Hemost., 1997, 23(1), 45-9.
95. Panos, R. J.; Mortenson, R. L.; Niccoli, S. A.; King, T. E. Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med., 1990, 88(4), 396-404.
96. Reed, A.; Snell, G. I.; McLean, C.; Williams, T. J. Outcomes of patients with interstitial lung disease referred for lung transplant assessment. Intern. Med. J., 2006, 36(7), 423-30.
97. Kubo, H.; Nakayama, K.; Yanai, M.; Suzuki, T.; Yamaya, M.; Watanabe, M.; Sasaki, H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest, 2005, 128(3), 1475-82.
98. Misra, H. P.; Rabideau, C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell Biochem., 2000, 204(1-2), 119-26.
99. Margolin, S. B.; Lefkowitz, S. Pirfenidone: a novel pharmacologic agent for prevention and resolution (removal) of lung fibrosis. FASEB J., 1994, 8(4), A117.
100. Kehrer, J. B.; Margolin, S. B. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol. Lett., 1997, 90(2-3), 125-32.
101. Schelegle, E. S.; Mansoor, J. K.; Giri, S. Pirfenidone attenuates bleomycin-induced changes in pulmonary function in hamsters. Proc. Soc. Exp. Biol. Med., 1997, 216(3), 392-7.
102. Gurujeyalakshmi, G.; Hollinger, M. A.; Giri, S. N. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol., 1999, 276(2), L311-L318.
103. Iyer, S. N.; Gurujeyalakshmi, G.; Giri, S. N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther., 1999, 291(1), 367-73.
104. Spond, J.; Case, N.; Chapman, R. W.; Crawley, Y.; Egan, R. W.; Fine, J.; Hey, J. A.; Kreutner, W.; Kung, T.; Wang, P.; Minnicozzi, M. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm. Pharmacol. Ther., 2003, 16(4), 207-14.
105. Iyer, S. N.; Hyde, D. M.; Giri, S. N. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 2000, 24(5), 477-91.
106. Nakazato, H.; Oku, H.; Yamane, S.; Tsuruta, Y.; Suzuki, R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur. J. Pharmacol., 2002, 446(1-3), 177-85.
107. Oku, H.; Nakazato, H.; Horikawa, T.; Tsuruta, Y.; Suzuki, R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol., 2002, 446(1-3), 167-76.
108. Kakugawa, T.; Mukae, H.; Hayashi, T.; Ishii, H.; Abe, K.; Fujii, T.; Oku, H.; Miyazaki, M.; Kadota, J.; Kohno, S. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur. Respir. J., 2004, 24(1), 57-65.
109. Raghu, G.; Johnson, W. C.; Lockhart, D.; Mageto, Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med., 1999, 159(4), 1061-9.
110. Nagai, S.; Hamada, K.; Shigematsu, M.; Taniyama, M.; Yamauchi, S.; Izumi, T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med., 2002, 41(12), 1118-23.
111. Azuma, A.; Nukiwa, T.; Tsuboi, E.; Suga, M.; Abe, S.; Nakata, K.; Taguchi, Y.; Nagai, S.; Itoh, H.; Ohi, M.; Sato, A.; Kudoh, S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2005, 171(9), 1040-7.
112. Taniguchi, H.; Ebina, M.; Kondoh, Y.; Ogura, T.; Azuma, A.; Suga, M.; Taguchi, Y.; Takahashi, H.; Nakata, K.; Sato, A.; Takeuchi, M.; Raghu, G.; Kudoh, S.; Nukiwa, T.; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J., 2010, 35(4), 821-9.
113. Chen, S. J.; Chen, Y. F.; Meng, Q. C.; Durand, J.; Dicarlo, V. S.; Oparil, S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol., 1995, 79(6), 2122-31.
114. Helset, E.; Lindal, S.; Olsen, R.; Myklebust, R.; Jorgensen, L. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. Am. J. Physiol., 1996, 271(4), L538-L546.
115. Shi-Wen, X.; Denton, C. P.; Dashwood, M. R.; Holmes, A. M.; Bou-Gharios, G.; Pearson, J. D.; Black, C. M.; Abraham, D. J. Fibroblast matrix gene expression and connective tissue remodelling: role of endothelin-1. J. Invest. Dermatol., 2001, 116(3), 417-25.
116. Clozel, M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann. Med., 2003, 35(8), 605-13.
117. Giaid, A.; Michel, R. P.; Stewart, D. J.; Sheppard, M.; Corrin, B.; Hamid, Q. Expression of endothelin-1 in the lungs of patients with cryptogenic fibrosing alveolitis. Lancet, 1993, 341(8860), 1550-4.
118. Park, S. H.; Saleh, D.; Giaid, A.; Michel, R. P. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med., 1997, 156(2), 600-8.
119. King, T. E. Jr; Behr, J.; Brown, K. K.; du Bois, R. M.; Lancaster, L.; de Andrade, J. A.; Stähler, G.; Leconte, I.; Roux, S.; Raghu, G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2008, 177(1), 75-81.
120. Raghu, G.; King, T. E. Jr; Behr, J.; Brown, K. K.; du Bois, R. M.; Leconte, I.; Roux, S.; Swigris, J. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur. Respir. J., 2010, 35(1), 118-23.
121. Piguet, P. F. Cytokines involved in pulmonary fibrosis. Int. Rev. Exp. Pathol., 1993, 34(B), 173-81.
122. Piguet, P. F.; Vesin, C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J., 1994, 7(3), 515-8.
123. Fujita, M.; Shannon, J. M.; Morikawa, O.; Gauldi, J.; Hara, N.; Mason, R. J. Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am. J. Respir. Cell. Mol. Biol., 2003, 29(6), 669-76.
124. Piguet, P. F.; Ribaux, C.; Karpuz, V.; Grau, G. E.; Kapanci, Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am. J. Pathol., 1993, 143(3), 651-5.
125. Kapanci, Y.; Desmouliere, A.; Pache, J. C.; Redard, M.; Gabbiani, G. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am. J. Respir. Crit. Care Med., 1995, 152(6), 2163-9.
126. Raghu, G.; Brown, K. K.; Costabel, U.; Cottin, V.; du Bois, R. M.; Lasky, J. A.; Thomeer, M.; Utz, J. P.; Khandker, R. K.; McDermott, L.; Fatenejad, S. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med., 2008, 178(9), 948-55.
127. Jiang, H. D.; Guang, H. S. MS80, a novel sulphated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-beta 1both in vitro and in vivo. Acta Pharmacol. Sin., 2009, 30(7), 973-9.
128. Wang, R.; Ibarra-Sunga, O.; Verlinski, L.; Pick, R.; Uhal, B. D. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by caspase inhibitor. Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 279(1), L143-L151.
129. Molteni, A.; Ward, W. F.; Ts'ao, C. H.; Solliday, N. H.; Dunne, M. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc. Soc. Exp. Biol. Med., 1985, 180(1), 112-20.
130. Molteni, A.; Moulder, J. E.; Cohen, E. F.; Ward, W. F.; Fish, B. L.; Taylor, J. M.; Wolfe, L. F.; Brizio-Molteni, L.; Veno, P. Control of radiation-induced pneumopathy and lung fibrosis by angiotensinconverting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int. J. Radiat. Biol., 2000, 76(4), 523-32.
131. Uhal, B. D.; Wang, R.; Laukka, J.; Zhuang, J.; Soledad-Conrad, V.; Filippatos, G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol. Toxicol., 2003, 92(2), 81-7.
132. Blanco-Colio, L. M.; Tunon, J.; Martin-Ventura, J. L.; Egido, J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int., 2003, 63(1), 12-23.
133. Hilgendorff, A.; Muth, H.; Parviz, B.; Staubitz, A.; Haberbosch, W.; Tillmanns, H.; Holschermann, H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int. J. Clin. Pharmacol. Ther., 2003, 41(9), 397-401.
134. Watts, K. L.; Sampson, E. M.; Schultz, G. S.; Spiteri, M. A. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am. J. Respir. Cell Mol. Biol., 2005, 32(4), 290-300.
135. Nadrous, H. F.; Ryu, J. H.; Douglas, W. W.; Decker, P. A.; Olson, E. J. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest, 2004, 126(2), 438-46.
136. Wilborn, J.; Bailie, M.; Coffey, M.; Burdick, M.; Strieter, R.; Peters-Golden, M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have diminished capacity to synthesize prostagladin E2 and to express cyclooxygenase-2. J. Clin. Invest., 1996, 95(4), 1861-8.
137. Peters-Golden, M.; Bailie, M.; Marshall, T.; Wilke, C.; Phan, S. H.; Toews, G. B.; Moore, B. B. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med., 2002, 165(2), 229-35.
138. Failla, M.; Genovese, T.; Mazzon, E.; Gili, E.; Muià, C.; Sortino, M.; Crimi, N.; Caputi, A. P.; Cuzzocrea, S.; Vancheri, C. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir. Res., 2006, 7, 137.
139. Koch, H. P. Thalidomide and congeners as anti-inflammatory agents. Prog. Med. Chem., 1985, 22, 165-242.
140. Sampaio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., 1991, 173(3), 699-703.
141. Haslett, P. A. J.; Corral, L. G.; Albert, M.; Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med., 1998, 187(11), 1885-92.
142. Corral, L. G.; Haslett, P. A.; Muller, G. W.; Chen, R.; Wong, L. M.; Ocampo, C. J.; Patterson, R. T.; Stirling, D. I.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol., 1999, 163(1), 380-6.
143. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91(9), 4082-5.
144. Ye, Q.; Chen, B.; Tong, Z.; Nakamura, S.; Sarria, R.; Costabel, U.; Guzman, J. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur. Respir. J., 2006, 28(4), 824-31.
145. Tabata, C.; Tabata, R.; Kadokawa, Y.; Hisamori, S.; Takahashi, M.; Mishima, M.; Nakano, T.; Kubo, H. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J. Immunol., 2007, 179(1), 708-14.
146. Horton, M. R.; Danoff, S. K.; Lechtzin, N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax, 2008, 63(8), 749.
147. Jenkins, R. G.; Su, X.; Su, G.; Scotton, C. J.; Camerer, E.; Laurent, G. J.; Davis, G. E.; Chamber, R. C.; Matthay, M. A.; Sheppard, D. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes lung injury. J. Clin. Invest., 2006, 116(6), 1606-14.
148. Bonniaud, P.; Margetts, P. J.; Kolb, M.; Schroeder, J. A.; Kapoun, A. M.; Damm, D.; Murphy, A.; Chakravarty, S.; Dugar, S.; Higgins, L.; Protter, A. A.; Gauldie, J. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med., 2005, 171(8), 889-98.
149. Kolb, M.; Margetts, P. J.; Sime, P. J.; Gauldie, J. Proteogylcans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic response to bleomycin. Am. J. Physiol. Lung Cell Mol. Physiol., 2001, 280(6), L1327-L1334.
150. Daniels, C. E.; Wilkes, M. C.; Edens, M.; Kottom, T. J.; Murphy, S. J.; Limper, A. H.; Leof, E. B. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycinmediated lung fibrosis. J. Clin. Invest., 2004, 114(9), 1308-16.
151. Aono, Y.; Nishioka, Y.; Inayama, M.; Ugai, M.; Kishi, J.; Uehara, H.; Izumi, K.; Sone, S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med., 2005, 171(11), 1279-85.
152. Daniels, C. E.; Lasky, J. A.; Limper, A. H.; Mieras, K.; Gabor, E.; Schoreder, D. R.; Imatinib-IpF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebocontrolled trial results. Am. J. Respir. Crit. Care Med., 2009, 181(6), 604-10.
153. Hilberg, F.; Roth, G. J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W. J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res., 2008, 68(12), 4774-82.
154. Tabata, C.; Kadowaka, Y.; Tabata, R.; Takahashi, M.; Okoshi, K.; Sakai, Y.; Mishima, M.; Kubo, H. All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2006, 174(12), 1352-60.
155. Phillips, R. J.; Burdick, M. D.; Hong, L.; Lutz, M. A.; Murray, L. A.; Xue, Y. Y.; Belperio, J. A.; Keane, M. P.; Strieter, R. M. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest., 2004, 114(3), 438-46.
156. Crockett, A. J.; Cranston, J. M.; Antic, N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst. Rev., 2001, CD002883.
157. Polonski, L.; Krzywiecki, A.; Tendera, M.; Cwiertka, P.; Oklek, K.; Wodniecki, J. Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. I. Effect on the course of the primary disease and on pulmonary circulation. Pol. Arch. Med. Wewn., 1995, 94(4), 331-6.
158. Holland, A.; Hill, C. Physical training for interstitial lung disease. Cochrane Database Syst. Rev., 2008, CD006322.
159. Holland, A. E.; Hill, C. J.; Conron, M.; Munro, P.; McDonald, C. F. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax, 2008, 63(6), 549-54.
160. Rangappa, P.; Moran, J. L. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit. Care Resusc., 2009, 11(2), 102-9.
161. Mollica, C.; Paone, G.; Conti, V.; Ceccarelli, D.; Schmid, D.; Mattia, P.; Perrone, N.; Petroianni, A.; Sebastiani, A.; Cechini, L.; Orsetti, R.; Terzano, C. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration, 2010, 79(3), 209-15.
162. Moderno, E. V.; Yamaguti, W. P.; Schettino, G. P.; Kairalla, R. A.; Martins, M. A.; Carvalho, C. R.; Carvalho, C. R. Effect of proportional assisted ventilation on exercise performance in idiopathic pulmonary fibrosis. Respir. Med., 2010, 104(1), 134-41.
163. Orens, J. B.; Shearon, T. H.; Freudenberger, R. S.; Conte, J. V.; Bhorade, S. M.; Ardehali, A. Thoracic organ transplantation in the United States, 1995-2004. Am. J. Transplant., 2006, 6(5), 1188-97.
164. Meyers, B. F.; Lynch, J. P.; Trulock, E. P.; Guthrie, T.; Cooper, J. D.; Patterson, G. A. Perioperative complications after living donor lobectomy. J. Thorac. Cardiovasc. Surg., 2000, 120(5), 909-15.
165. O'Beirne, S.; Counihan, I. P.; Keane, M. P. Interstitial lung disease and lung transplantation. Semin. Respir. Crit. Care Med., 2010, 31(2), 139-46.
166. Mogulkoc, N.; Brutsche, M. H.; Bishop, P. W.; Greaves, S. M.; Horrocks, A. W.; Egan, J. J.; Greater Manchester Pulmonary Fibrosis Consortium. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am. J. Respir. Crit. Care Med., 2001, 164(1), 103-8.